Slingshot members are tracking this event:
ZIOPHARM Announces Plans for Phase I Clinical Trial with CD33 CAR-T Cell Therapy Targeting Acute Myeloid Leukemia
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
ZIOPHARM intends to further expand its clinical programs in the area of natural killer (NK) cells and a combination approach to its Ad-RTS-hlL-12 gene therapy using an immune checkpoint inhibitor through the remainder of 2016. Additionally, ZIOPHARM and Intrexon continue to advance preclinical efforts leveraging the Sleeping Beauty platform, the clinical-stage RheoSwitch (RTS), and improving cell manufacturing for the clinical applications of T cells engineered to express CAR and TCR, as well as off-the-shelf approaches.
Slingshot Insights Explained
Jul 12, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Cd33, Car-t Cell Therapy, Acute Myeloid Leukemia, Ad-rts-hll-12 Gene Therapy